News Search Results
Apr 02, 2025, 08:00 ET Flamingo Therapeutics Announces Participation in Upcoming Investor Conferences
undruggable transcription factors and long non-coding RNAs. Flamingo has an alliance with Ionis Pharmaceuticals and is supported by well-known biotechnology investors including Abrdn (formerly funds managed by Tekla Capital Management LLC), Andera Partners, Bpifrance Large Venture, Bpifrance through
More news about: Flamingo Therapeutics
Apr 02, 2025, 05:00 ET Landmark Bio Acquired by Artis BioSolutions to Expand Manufacturing and Commercialization of Advanced Therapies
Bio has built a robust platform to address persistent bottlenecks in advanced therapy development, serving as a partner to academic institutions, biotechnology companies, and global biopharma firms. The organization was established by leaders from academia, industry, and Boston's
More news about: Landmark Bio
Apr 02, 2025, 05:00 ET Change in Management: Exyte announces Katrien Verlinden as new President of its Global Business Unit Advanced Technology Facilities
developed over more than a century, the company serves clients in the sophisticated markets of semiconductors, battery cells, pharmaceuticals, biotechnology, and data centers. Exyte offers a full range of services from consulting to managing the implementation of built complete solutions with the highest
More news about: Exyte
Apr 02, 2025, 05:00 ET Change in Management: Exyte announces Katrien Verlinden as new President of its Global Business Unit Advanced Technology Facilities
developed over more than a century, the company serves clients in the sophisticated markets of semiconductors, battery cells, pharmaceuticals, biotechnology, and data centers. Exyte offers a full range of services from consulting to managing the implementation of built complete solutions with the highest
More news about: Exyte
Apr 01, 2025, 16:05 ET Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President
Dr. Eckelman leaves the Company to establish a newly-formed private biotechnology company, where he will be founder and Chief Executive Officer. Inhibrx and the new company have entered into an exclusive license agreement for
More news about: Inhibrx Biosciences, Inc.
Apr 01, 2025, 13:54 ET SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 4, 2024, both dates inclusive
More news about: THE ROSEN LAW FIRM, P. A.
Apr 01, 2025, 13:05 ET ICLR INVESTOR NOTICE: ICON PLC Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
insufficient to shield ICON from the adverse effects of a significant market downturn; (iii) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Robbins Geller Rudman & Dowd LLP
Apr 01, 2025, 10:45 ET US Single-use Assemblies Market worth US$1658.8 million by 2029 with 15.0% CAGR | MarketsandMarkets™
growth is driven by the increasing preference for outsourcing research and manufacturing activities among pharmaceutical, biopharmaceutical, and biotechnology companies. CROs and CMOs provide a range of services, including drug discovery, clinical-scale manufacturing, preclinical and clinical trials, and
More news about: MarketsandMarkets
Apr 01, 2025, 10:15 ET Testing, Inspection, and Certification (TIC) Market worth $282.76 billion by 2030 - Exclusive Report by MarketsandMarkets™
complexity of medical devices, pharmaceuticals, and biotechnology. Stricter regulations, like FDA guidelines and the EU MDR, are pushing the need for thorough testing and certification. Gene therapy and personalized medicine are some of the biotechnology developments requiring TIC services for safety and
More news about: MarketsandMarkets
Apr 01, 2025, 10:15 ET INTRODUCING GODDESS MAINTENANCE CO: THE NEXT BIG DISRUPTOR IN BIOTECH BEAUTY
and K18 Hair. Connaghan and Russell are acclaimed entrepreneurs known for their innovative solutions and strategic partnerships. With a focus on biotechnology, they continue to foster groundbreaking advancements in skin and hair care. Their company, Next8 Investments, aims to support emerging founders
More news about: Goddess Maintenance Co.
Apr 01, 2025, 10:03 ET DNA Data Storage Market is expected to generate a revenue of USD 6,241.39 Million by 2032, Globally, at 74.48% CAGR: Verified Market Research®
writing procedures are further accelerating market adoption. This technical advancement is promoting partnerships between storage providers and biotechnology companies. Rising Demand for Sustainable and Long-Term Storage Solutions: Conventional data storage mediums, like magnetic tapes and
More news about: Verified Market Research
Apr 01, 2025, 10:01 ET High Content Screening Market worth US$2.19 billion in 2030 with 7.5% CAGR | MarketsandMarkets™
settings. By Based on end user, the market is segmented into pharmaceutical & biotechnology companies, academic & government institutes, and CROs & CDMOs. pharmaceutical & biotechnology companies dominated the segment in 2024 and is anticipated to grow at the highest CAGR during
More news about: MarketsandMarkets
Apr 01, 2025, 10:00 ET Yingli Pharma Announces Successful End-of-Phase 2 Meeting with FDA and Clearance of Global Multi-center Phase 3 Registration Study Design of Linperlisib for the Treatment of Relapsed and/or Refractory Peripheral T-cell Lymphoma
April 1, 2025 /PRNewswire/ -- Shanghai Yingli Pharmaceutical Co., Ltd. (Yingli Pharma), a clinical stage biotechnology company developing oral small molecule drugs for cancer, metabolic, and immune diseases, announced today that it has received clearance from the
More news about: Shanghai Yingli Pharmaceutical Co., Ltd.
Apr 01, 2025, 09:05 ET Flywheel Releases Enhanced Multimodal Functionality with Video Capabilities to Expand Research Innovation for Life Sciences
data management, automating research workflows and preparing data for AI development. Flywheel's comprehensive solution allows pharmaceutical and biotechnology companies, academic medical centers, AI developers and medical device manufacturers to realize optimum value out of their imaging data assets. For
More news about: Flywheel
Apr 01, 2025, 09:00 ET GeminiBio Expands Board with Addition of Industry Veteran
critical customer-oriented insights in the Pharma and Biotech industry. Jeffrey Gatz is a seasoned executive with extensive experience in the biotechnology and life science sectors. He spent 26 years as CEO of BioIVT, a leading global provider of biological products for life sciences and pharmaceutical
More news about: Gemini Bioproducts, LLC
Apr 01, 2025, 08:41 ET Tequity Advises Stratogent on Acquisition by PTP
harness cloud technology for strategic growth. With deep expertise in AWS, PTP delivers secure, scalable, and compliant solutions tailored to the biotechnology industry. About Tequity Tequity Advisors advises enterprise B2B SaaS, Cloud, and IT companies on strategic M&A to drive
More news about: Tequity Advisors
Apr 01, 2025, 08:05 ET Avantor® Showcases Scalable Fluid Handling Innovations at INTERPHEX
for the life sciences and advanced technology industries, announces its presence at INTERPHEX, the premier annual gathering of pharmaceutical, biotechnology, and device development and manufacturing professionals. The company will showcase fluid handling technologies that support every step of the bioprocessing
More news about: Avantor and Financial News
Apr 01, 2025, 08:00 ET Anixa Biosciences to Present at the Jones Las Vegas Healthcare and Technology Innovation Conference on April 9th
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced its participation in the Jones Las Vegas Healthcare and Technology Innovation
More news about: Anixa Biosciences, Inc.
Apr 01, 2025, 08:00 ET Flagship Pioneering Announces Agreement Between Pioneering Medicines and Pfizer to Discover Potential Novel, Selective Inhibitors for Autoimmune Disease
Sana Biotechnology (NASDAQ: SANA),
More news about: Flagship Pioneering
Apr 01, 2025, 07:00 ET Adcendo ApS Announces Changes in Board of Directors and Strengthens Executive Leadership Team
Laura Shawver Laura is a pioneer in healthcare who brings over two decades of leadership experience in biotechnology and patient advocacy, creating new paradigms in research and treatment for cancer and other serious diseases. As a scientist, she conducted research
More news about: Adcendo
Apr 01, 2025, 07:00 ET Adcendo ApS Announces Changes in Board of Directors and Strengthens Executive Leadership Team
Laura Shawver Laura is a pioneer in healthcare who brings over two decades of leadership experience in biotechnology and patient advocacy, creating new paradigms in research and treatment for cancer and other serious diseases. As a scientist, she conducted research
More news about: Adcendo
Apr 01, 2025, 06:30 ET Immunic, Inc. to Participate in Scientific and Industry Conferences in April
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today
More news about: Immunic, Inc.
Apr 01, 2025, 06:00 ET IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events
Executive Officer and Darrin Beaupre, Chief Medical Officer, hosted by Gregory Renza, M.D., Director and Senior Biotechnology Research AnalystStifel 2025 Virtual Targeted Oncology ForumTuesday, April 8th,
More news about: IDEAYA Biosciences, Inc.
Apr 01, 2025, 05:45 ET Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sana Biotechnology, Inc.(SANA) Shareholders
April 1, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.
More news about: Levi & Korsinsky, LLP
Apr 01, 2025, 05:45 ET ICON Public Limited Company Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 11, 2025 to Discuss Your Rights - ICLR
insufficient to shield the Company from the adverse effects of a significant market downturn; (c) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Levi & Korsinsky, LLP